Lyra Therapeutics Stock Performance
| LYRA Stock | USD 0.18 0.01 5.88% |
Lyra Therapeutics has a performance score of 3 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.0071, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Lyra Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Lyra Therapeutics is expected to be smaller as well. Lyra Therapeutics right now secures a risk of 4.27%. Please verify Lyra Therapeutics maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to decide if Lyra Therapeutics will be following its current price movements.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lyra Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Lyra Therapeutics may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 23.7 M |
Lyra |
Lyra Therapeutics Relative Risk vs. Return Landscape
If you would invest 17.00 in Lyra Therapeutics on December 22, 2024 and sell it today you would earn a total of 1.00 from holding Lyra Therapeutics or generate 5.88% return on investment over 90 days. Lyra Therapeutics is currently generating 0.184% in daily expected returns and assumes 4.2734% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Lyra, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lyra Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lyra Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lyra Therapeutics, and traders can use it to determine the average amount a Lyra Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0431
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LYRA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.27 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Lyra Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lyra Therapeutics by adding it to a well-diversified portfolio.
Lyra Therapeutics Fundamentals Growth
Lyra Stock prices reflect investors' perceptions of the future prospects and financial health of Lyra Therapeutics, and Lyra Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lyra Stock performance.
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (46.73) % | ||||
| Current Valuation | 4.27 M | ||||
| Shares Outstanding | 65.88 M | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 7.16 X | ||||
| Revenue | 1.53 M | ||||
| EBITDA | (60.26 M) | ||||
| Cash And Equivalents | 120.67 M | ||||
| Cash Per Share | 3.79 X | ||||
| Total Debt | 34.38 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (70.01 M) | ||||
| Earnings Per Share | (1.43) X | ||||
| Total Asset | 66.35 M | ||||
| Retained Earnings | (404.79 M) | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 4.82 M | ||||
About Lyra Therapeutics Performance
By analyzing Lyra Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Lyra Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lyra Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lyra Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Lyra Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 60 people.Things to note about Lyra Therapeutics performance evaluation
Checking the ongoing alerts about Lyra Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lyra Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lyra Therapeutics has some characteristics of a very speculative penny stock | |
| Lyra Therapeutics had very high historical volatility over the last 90 days | |
| Lyra Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.53 M. Net Loss for the year was (93.44 M) with loss before overhead, payroll, taxes, and interest of (42.23 M). | |
| Lyra Therapeutics currently holds about 120.67 M in cash with (70.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Lyra Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lyra Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Lyra Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lyra Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lyra Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lyra Therapeutics' stock. These opinions can provide insight into Lyra Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lyra Stock analysis
When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |